The presence of at least 2 of these symptoms indicates an Alcohol Use Disorder (AUD). 1 . Alcohol is often taken in larger amounts or over a longer period than was intended. 2. There is a persistent desire or unsuccessful efforts to cut down or control alcohol use. 3 . A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects. 4 . Craving, or a strong desire or urge to use alcohol 5. Recurrent alcohol use resulting in a failure to fulfi ll major role obligations at work, school, or home. 6 . Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol. 7. Important social, occupational, or recreational activities are given up or reduced because of alcohol use. 8. Recurrent alcohol use in situations in which it is physically hazardous. 9. Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol.
10. Tolerance, as defi ned by either of the following: a) A need for markedly increased amounts of alcohol to achieve intoxication or desired effect. b) A markedly diminished effect with continued use of the same amount of alcohol.
Withdrawal, as manifested by either of the following:
a) The characteristic withdrawal syndrome for alcohol (refer to criteria A and B of the criteria set for alcohol withdrawal) b) Alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms. of the glutamate system occurs. N-methyl-d-aspartate (NMDA) receptors become upregulated, and the concentration of the neurotransmitter glutamate increases. 7 When alcohol consumption ceases, these processes all lead to an unopposed neuronal excitation and the autonomic hyperactivity that occur during AWS. 6 
Clinical Manifestations
The cluster of signs and symptoms that characterizes AWS is classifi ed as mild, moderate, or severe. The diagnostic criteria and classifi cation of AWS by the American Psychiatric Association 2(pp499-501) are presented in Table 2 . Mild signs and symptoms such as tremor, anxiety, diaphoresis, tachycardia, and sleep disturbances typically occur in the fi rst 24 hours after the last intake of alcohol. 8 Progression to moderate and severe AWS may include fever, confusion, clouding of the sensorium, hallucinations, and seizures. The signs and symptoms that occur with moderate and severe withdrawal are the result of neuronal excitation. 9 The most severe and feared complication of AWS is delirium tremens, which is usually manifested within 2 to 5 days after the last drink. 9 Patients with delirium tremens may have a fl uctuating level of consciousness, with attention and cognitive defi cits, hallucinations, confusion, and hypertension. 9 If delirium tremens is poorly managed, cardiovascular and respiratory collapse, arrhythmias, dehydration, electrolyte imbalances, and multiorgan dysfunction may occur. 10 The mortality rate for patients with untreated delirium tremens is high (5%-15%), but with improved recognition and management, mortality has decreased to approximately 1% to 2%. 8 According to estimates, delirium tremens may develop in 5% to 20% of patients with AWS. 8 However, the true incidence among critically ill patients is hard to measure. 8 
Identifying ICU Patients at Risk for Alcohol Withdrawal
The key to managing alcohol withdrawal effectively is the early identifi cation of an AUD gleaned from the patient's medical history. Unfortunately, a patient's history of alcohol consumption is often poorly obtained, not detailed enough, or not obtained at all. [11] [12] [13] [14] For example, in a retrospective review 12 of approximately 2000 trauma patients, only 7.3% of patients had an adequate history taken that would have highlighted an AUD. In the ICU, alcohol histories may be missed for several reasons. The inability of patients to communicate because of sedation, mechanical ventilation, and delirium is clearly a barrier. In addition, Broyles et al 11 found that clinicians either do not question enough about drug and alcohol intake or use selective questioning based on stereotyping of patients. The use of screening tools (Table 3) such as the CAGE questionnaire, the Alcohol Use Disorders Identifi cation Test (AUDIT), the AUDIT-C, the AUDIT-PC, and the Michigan Alcoholism Screening Test improves the identifi cation of an AUD during history taking. Unfortunately none of these tools has been developed or validated in critically ill patients. [15] [16] [17] Anecdotally, nurses at the bedside are the care providers who often become aware of clues from a patient's family about a patient's alcohol use. 18 Critical care nurses quickly establish rapport and relationships with their patients and the patients' families and are extremely well placed to gain information about alcohol use. Regrettably, only a single study 19 has shown that the completion of alcohol screening by family members could be as effective and valid as patient self-reporting.
The development of a valid and effective tool that nurses could use to glean important alcohol histories from patients or the patients' families would be of great benefi t. If patients at risk are identifi ed at the time of admission, nurses will be able to detect signs and symptoms of an emerging AWS and initiate treatment early. This practice might halt the progression from mild to severe withdrawal and prevent delirium tremens. 18, 20 Use of Serum Biomarkers to Detect an AUD A serum laboratory test that could highlight chronic alcohol use would be helpful, especially when an alcohol history is unobtainable. Laboratory tests such as serum ethanol levels only reveal recent alcohol consumption, not the chronic intake of alcohol that predisposes to withdrawal. 21 Other tests such as mean corpuscular volume and serum concentrations of γ-glutamyl transpeptidase and carbohydrate-defi cient transferrin have been widely studied in a variety of patient populations. 22 However the tests have variable predictive value and poor utility. 22, 23 In 2 studies, 24, 25 serum biomarkers, including carbohydrate-defi cient transferrin, in trauma patients were evaluated. Although both studies revealed that patients with higher levels of the transferrin had an increased length of stay and complications, the levels were not predictive of which patients would go into withdrawal. Findings such as these 24, 25 continue to reinforce the importance of the alcohol history.
Predicting Alcohol Withdrawal in Critically Ill Patients
Not every patient with an AUD will progress to withdrawal, just as not every patient who undergoes withdrawal progresses to delirium tremens. 26 Thus, being able to predict who is and who is not at greater risk for withdrawal would be advantageous. Multiple risk factors, including a history of withdrawal seizures, structural brain lesions, multiple detoxifi cation episodes, and severe withdrawal or delirium tremens during past withdrawals have been predictive of future severe withdrawal. 27, 28 A process known as "kindling" is postulated to be responsible for the increasing severity of withdrawal with each detoxifi cation episode. 29 Some researchers have taken these prediction factors and devised tools for identifying patients at risk for more severe withdrawal. Maldonado et al 28 recently devised the Prediction of Alcohol Withdrawal Severity Scale; the scale is based on 10 factors identifi ed through the literature. Unfortunately, this scale was validated in medical inpatients only, and so its use in ICU patients is limited. Although research on risk factors in ICU patients is limited, care providers generally accept that patients who have experienced severe withdrawal, delirium tremens, or seizures during past Symptom-triggered therapy in combination with an alcohol withdrawal assessment scale has been superior to fixed dose scheduling in clinical practice.
withdrawal episodes are most at risk for severe withdrawal. 27 Therefore, asking patients if they have experienced events such as seizures or delirium tremens during past withdrawals or detoxification episodes is important. The information will highlight any signs and symptoms experienced in the past that may be predictive of the manifestations of current and future withdrawals.
Identifying Critically ill Patients With AWD
Identifying critically ill patients who are in active withdrawal presents further challenges. Conditions such as sepsis, intracranial hemorrhage, meningitis, stroke, traumatic brain injury, and metabolic derangements may have signs and symptoms similar to those of AWS. For example, tremor, diaphoresis, altered vital signs, fever, and delirium are also evident in critical illness. Differentiating between AWS and the result of disease is thus difficult. 30 A total of 2 older retrospective studies and 1 case series of critically ill patients have described this challenge. [31] [32] [33] Bostwick and Lapid 31 presented 4 cases of critically ill patients who had a diagnosis of AUD and were placed on an AWS assessment protocol. Despite seemingly adequate treatment of AWS, the condition of all 4 patients continued to worsen. Once a thorough workup had been completed, undiagnosed medical conditions, rather than worsening AWS, were revealed as the cause of the signs and symptoms. The important point is that a worsening clinical condition in a patient with AWS should not always be assumed to be related to withdrawal. This point is particularly important in the ICU, where patients are at great risk for adverse changes in clinical condition because of their critical illness. Any patient undergoing withdrawal whose condition worsens despite therapy must undergo a thorough examination and workup to exclude a missed acute medical condition. 34, 35 Treatment
Benzodiazepines
Benzodiazepines are considered the first-line therapy in the treatment of AWS. 36 The results of 2 metaanalyses 37, 38 have shown that these drugs are better in the control of signs and symptoms and more effective than placebo in halting the progression to delirium tremens. The mechanism of action is directly related to the interaction of benzodiazepines with brain GABA receptors. This interaction leads to an increase in GABA transmission, which reduces central nervous system excitability and the risk for seizures and prevents the progression to delirium tremens. 37 Although no evidence indicates that one benzodiazepine is better than another, the choice of a particular drug should be tailored to the patient. 39 For example, rapid-acting benzodiazepines such as diazepam, lorazepam, and alprazolam may be more appropriate in patients when rapid symptom control is needed. 36 Conversely, agents such as chlordiazepoxide and diazepam may be more effective in providing a smoother detoxification course and reducing rebound withdrawal symptoms. 36 Unfortunately, both chlordiazepoxide and diazepam undergo hepatic metabolism. The active metabolite may accumulate in the liver in patients with hepatic disease if the dose of the drug is not adjusted. 39 Instead, alprazolam and lorazepam may be more appropriate for patients with liver dysfunction. 36 Unfortunately, recommendations and guidelines on the optimum choice and dose of drug for critically ill patients with AWS remain limited. 39 However, administration of benzodiazepines via the intravenous route may be preferable in the ICU because of the rapid onset of action and more predictable bioavailability. 39 Symptom-Triggered Therapy and the CIWA-ar Scale Administration of benzodiazepines according to symptom-triggered therapy in combination with an alcohol withdrawal assessment scale has been superior to fixed dose scheduling in a variety of community and hospital settings. [40] [41] [42] [43] Evaluations 44-46 of symptomtriggered therapy in the ICU have predominantly focused on the use of the CIWA-ar scale. The CIWA-ar remains the most widely used scale in clinical practice both inside and outside the ICU.
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The CIWA-ar scale is a 10-item scale that can be used to assess a patient every 30 to 60 minutes 43 (Table 4) . A score less than 8 indicates mild withdrawal; moderate withdrawal is indicated by scores of 8 to 15, and scores greater than 20 indicate severe withdrawal. 39 Typically, drug therapy is started in patients who have a score greater than 8. Despite widespread use of the CIWA-ar scale in the ICU, only 4 randomized clinical studies [44] [45] [46] [47] and 1 retrospective cohort study 48 that included use of the scale in patients with AWS have been published. In one of the early studies, Spies et al 44 used the CIWA-ar scale to assess and guide therapy. Patients were assigned to 1 of 4 groups: clonidine and flunitrazepam, haloperidol and chlormethiazole, haloperidol and flunitrazepam, or ethanol alone. The efficacy of therapy did not differ between the drug regimens, and for most patients, AWS was adequately managed. The rate of tracheobronchitis was increased, however, among patients treated with chlormethiazole, a result of bronchial hypersecretion.
In another study, Spies et al 45 evaluated the management of 159 critically ill trauma patients who were randomized to treatment with clonidine and flunitrazepam, haloperidol and chlormethiazole, or haloperidol and flunitrazepam.
Overall, no regimen was more advantageous than another, and for most patients, therapy was effective (scores on the CIWA-ar scale decreased to <20). However both early studies 44, 45 included only a narrowly defined cohort of ICU patients, predominantly patients who were young (mainly trauma patients), had low-acuity illness, and were not intubated.
In a third study, Spies et al 46 reported similar results among 44 trauma-surgical ICU patients in a prospective, randomized double-blind trial comparing bolus versus fixed-dose infusion of flunitrazepam. In contrast to the patients in the earlier studies, the patients in this study 46 experienced much more complex withdrawal and had higher CIWA-ar scores, indicating a need for multimodal therapy and mechanical ventilation.
In summary, these studies revealed that the CIWA-ar scale can be a useful tool for critically ill patients undergoing AWS. Unfortunately, one drawback of the scale is that it remains unvalidated in this patient group. Although the studies by Spies et al [44] [45] [46] did show effective use of the scale in their selected cohorts of patients (mainly trauma), how the scale might be affected by other patient-related variables such as critical illness (eg, organ dysfunction, sepsis) is still unknown. A theoretical risk exists that signs and symptoms of critical illness might be mistaken for those of AWS, leading to falsely elevated scores on the CIWA-ar scale. 31, 32, 49 Such a mistake might lead to the inappropriate or overzealous administration of medications, with the risk of oversedation and other side effects. 32 To date, only 1 case series 32 and 1 older retrospective analysis 49 have alluded to this phenomenon. Still, cognizance of the potential for exaggerated scores on the CIWA-ar scale patients with critical illness is important. If the CIWA-ar scale is used, then scores must be analyzed within the wider context of each patient's signs and symptoms, with careful assessment and evaluation of response to treatment. The CIWA-ar scale should not be applied indiscriminately or without careful consideration in critically ill patients.
Severe AWS and Delirium Tremens
Evidence 50 indicates that patients who have a medical or surgical illness in whom AWS develops have a higher predisposition for more severe withdrawal and delirium tremens than do patients who have AWS only. Most likely the situation is the same for patients with a critical illness and AWS. However, in general, little research has been done on the influence of critical illness on delirium tremens and vice versa. 50 Most recently, Sohraby et al 48 reported the results of a retrospective cohort study of critically ill patients with severe AWS. The findings indicated that this population of patients may need additional drugs to manage severe withdrawal. Adjuvant therapy with anticonvulsants, neuroleptic agents, sedativehypnotics, antipsychotics, and α-agonists may be needed. However, the lack of large high-quality studies generally limits guidance on choice, combination, and recommended doses for these patients. 51 Gold et al 52 performed a retrospective cohort study on patients admitted to the ICU with delirium tremens refractory to benzodiazepines. One group of patients (n = 54) was treated before the institution of guidelines emphasizing escalating doses of diazepam in combination with lower doses of phenobarbital. The second group (n = 41) received benzodiazepines and higher doses of phenobarbital. The second group had a significant reduction in the need for intubation, and a trend toward decreased length of stay. In another randomized controlled trial, 53 treatment with benzodiazepines and phenobarbital in patients in the emergency department reduced the need for ICU admission. The long duration of action of phenobarbital may provide a smoother course of detoxification. 53 However, further research in critically Dexmedetomidine has become a promising agent in the management of AWS in the ICU in combination with benzodiazepines.
A drawback of using the CIWA-ar scale is that patients must be able to communciate symptom severity for 7 of the 10 items.
ill patients is warranted before recommendations can be made on the use of phenobarbital in the ICU. Recently, dexmedetomidine has become a promising agent in the management of AWS in the ICU in combination with benzodiazepines. Several case reviews and retrospective studies have been published. [54] [55] [56] [57] [58] [59] In a randomized controlled trial, Mueller et al 47 investigated the effectiveness of dexmedetomidine infusion (high dose vs low dose vs placebo) plus benzodiazepines in 24 patients with severe AWS. The sample included patients in severe withdrawal (defined as CIWA-ar scores >15) despite highdose drug treatment (>16 mg lorazepam in a 4-hour period). Both the CIWA-ar scale and the Riker SedationAgitation Scale were used to evaluate therapy. The results indicated that dexmedetomidine reduced the overall benzodiazepine dosages in the first 24 hours and AWS was effectively managed. However, any benefit in reducing the total amount of benzodiazepines during the rest of a patient's course of withdrawal was not evident. ICU and hospital lengths of stay were unchanged. Dexmedetomidine can be considered an effective, adjuvant therapy in the management of AWS; however, benzodiazepines remain the first-line treatment.
Propofol has also been recently evaluated in 2 retrospective analyses. 48, 52 Typically, the use of propofol has been reported in instances in which patients were refractory to massive doses of benzodiazepines. [60] [61] [62] [63] In a retrospective analysis of 64 intubated patients, Sohraby et al 48 compared propofol infusion plus benzodiazepine therapy with benzodiazepine monotherapy. They found that both drug regimens were effective but did not necessarily reduce AWS duration or length of stay, a result of a concomitant critical illness.
The reasons that patients may be refractory to benzodiazepines are still unknown. One theory is that GABA receptors become saturated once a certain dose threshold of benzodiazepines is met. 35 The action of propofol on N-methyl-d-aspartate and glutamate receptors may account for rapid symptom control via its effect on alternative receptors or an alternative metabolic pathway. 35 Unfortunately, if withdrawal becomes so severe that agents such as dexmedetomodine and propofol are needed, intubation and mechanical ventilation may be necessary. These procedures add another layer of complexity to the assessment and management of patients undergoing AWS.
Assessment of Intubated Patients With AWS
Another drawback of using the CIWA-ar scale is that patients must be able to communicate symptom severity for 7 of the 10 items. Clearly, this requirement is a problem for critically ill patients who are delirious, confused, and unable to communicate. The studies by Sohraby et al 48 and Mueller et al 47 are important in identifying how intubated patients with AWS can be assessed in the ICU. These studies 47, 48 were performed in a unique, complex group of patients (intubated for severe withdrawal), a sample often excluded from earlier studies. [44] [45] [46] Both Mueller et al and Sohraby et al used the CIWA-ar scale in alert, communicative, cognitively aware patients and the Riker Sedation-Agitation Scale, the Ramsey Agitation Scale, or the Richmond Agitation-Sedation Scale when patients could no longer communicate. Previously, Weinberg et al 64 used the 7-item Riker Sedation-Agitation Scale in a study of 50 trauma patients, and Elsing et al 65 used an adapted 4-item CIWA-ar scale in a study of 26 AWS patients in a medical ICU. Use of these tools 64, 65 has been neither validated nor described elsewhere.
Only 1 tool has been specifically designed for intubated, critically ill patients undergoing alcohol withdrawal: the Minnesota Detoxification Scale. DeCarolis et al 66 described the development and use of the scale in 36 medical ICU patients. The scale is limited, however, because it is based on only 1 single-center, retrospective study with only 36 patients and it remains unvalidated. Guidelines 67 and a systematic review 51 do support titrating medications to scores on a sedation-agitation scale and clinical judgment but do not describe which tool may be the best for patients undergoing withdrawal. Guidelines 68 on the management of sedation and delirium in critically ill patients not in acute withdrawal suggest using either the Riker Sedation-Agitation Scale or the Richmond AgitationSedation Scale.
Delirium detection scales such as the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) are highly sensitive and specific for detection of delirium in general ICU patients. 69 For the CAM-ICU, sensitivity is 80% (95% CI, 77.1-82.6), and specificity is (95% CI, 94.8-96.0) . The ICDSC has a sensitivity of 74%, and a specificity of 81% as a diagnostic screening tool for delirium in the ICU. 69 Compared with the CAM-ICU, the ICDSC was as effective in the detection of delirium but with slightly less specificity. However, neither the CAM-ICU nor the ICDSC have been validated in patients with AWS-related delirium. Nonetheless, Tolonen et al 59 successfully used the CAM-ICU in the management of 18 patients with alcohol-related delirium in the ICU. This study 59 was only a prospective series, however, and further studies are warranted.
Finally, the Delirium Detection Score (DDS) developed and validated by Otter et al 70 was refined from the CIWA-ar scale. The researchers and developers suggest that the DDS can be used in the ICU in patients with either alcoholrelated delirium or delirium of different etiology. Paupers et al 71 suggest that the score could be used with good validity and reliability. However, the DDS is such a recent tool, it requires further multicenter studies to confirm its external validity and generalizability before it can be widely adopted. It remains the only alcohol withdrawal assessment tool currently validated in ICU patients and of use in patients receiving mechanical ventilation. Until more research on delirium detection scales is performed on critically ill patients undergoing alcohol withdrawal, one scale cannot be recommended for use over another. Until more research is performed, nurses can continue to use any of the delirium detection scales together with clinical judgment, assessment, and the evaluation of treatment.
Conclusion
Important challenges are associated with caring for critically ill patients with AWS. The first step in identifying a patient with an AUD is obtaining a history of the patient's alcohol consumption. However, obtaining this history is poorly executed in clinical practice. Recognizing patients in active alcohol withdrawal is also difficult. The clinical manifestations of critical illness and AWS are often similar. Once AWS is diagnosed, the CIWA-ar scale can be used to assess and monitor response to therapy and the progression of signs and symptoms. Some patients may progress to delirium tremens and require multiple-drug therapies, intubation, and mechanical ventilation. The CIWA-ar scale can then no longer be used in these patients. Sedation-agitation scales and delirium detection tools have been used in AWS patients who are intubated or receiving mechanical ventilation. However, the efficacy and usefulness of the tools in patients with AWS or delirium tremens have not been evaluated. What may be of use is a large, methodologically sound study that provides validation of a tool or scale that can be used for AWS in critically ill patients.
Implications and Recommendations
A great need exists for further research in almost every aspect of AWS in critically ill patients. An important facet of caring for such patients is obtaining a thorough alcohol history early in their admission. Nurses are perfectly placed to obtain histories of alcohol consumption from patients or the patients' families. A tool that enables nurses to obtain the alcohol history would be of great benefit. Once AWS is diagnosed in a patient, a treatment plan must be developed. Astute nursing assessment, clinical judgment, and diligent monitoring for subtle changes in the patient's signs and symptoms are paramount. These steps are important for 2 reasons: first, to recognize the difference between what may be a worsening medical condition and worsening AWS; and second, to ensure worsening AWS is recognized early and use of adjunctive medications is started. A reasonable approach might be to use a severity assessment scale such as the CIWA-ar to guide and assess the response to these therapies. However scores must be viewed in the right clinical context and always in conjunction with excellent clinical judgment. Specific recommendations for sedation-agitation or delirium detection scales for AWS cannot be made at this juncture. However use of the CAM-ICU in conjunction with a sedation-agitation scale may be beneficial in AWS patients who are sedated, are being treated with mechanical ventilation, or are delirious. CCN
